S&P 500   3,295.47 (-0.90%)
DOW   28,989.73 (-0.58%)
QQQ   222.70 (-0.84%)
AAPL   318.31 (-0.29%)
FB   217.95 (-0.82%)
MSFT   165.04 (-1.01%)
GOOGL   1,466.17 (-1.25%)
NVDA   250.48 (-0.94%)
BABA   213.75 (-2.46%)
MU   57.76 (-2.43%)
GE   11.71 (-0.51%)
AMD   50.35 (-2.63%)
T   38.50 (-0.34%)
ACB   1.99 (-3.86%)
F   9.00 (-1.53%)
BAC   33.54 (-1.70%)
GILD   63.15 (-1.24%)
S&P 500   3,295.47 (-0.90%)
DOW   28,989.73 (-0.58%)
QQQ   222.70 (-0.84%)
AAPL   318.31 (-0.29%)
FB   217.95 (-0.82%)
MSFT   165.04 (-1.01%)
GOOGL   1,466.17 (-1.25%)
NVDA   250.48 (-0.94%)
BABA   213.75 (-2.46%)
MU   57.76 (-2.43%)
GE   11.71 (-0.51%)
AMD   50.35 (-2.63%)
T   38.50 (-0.34%)
ACB   1.99 (-3.86%)
F   9.00 (-1.53%)
BAC   33.54 (-1.70%)
GILD   63.15 (-1.24%)
S&P 500   3,295.47 (-0.90%)
DOW   28,989.73 (-0.58%)
QQQ   222.70 (-0.84%)
AAPL   318.31 (-0.29%)
FB   217.95 (-0.82%)
MSFT   165.04 (-1.01%)
GOOGL   1,466.17 (-1.25%)
NVDA   250.48 (-0.94%)
BABA   213.75 (-2.46%)
MU   57.76 (-2.43%)
GE   11.71 (-0.51%)
AMD   50.35 (-2.63%)
T   38.50 (-0.34%)
ACB   1.99 (-3.86%)
F   9.00 (-1.53%)
BAC   33.54 (-1.70%)
GILD   63.15 (-1.24%)
S&P 500   3,295.47 (-0.90%)
DOW   28,989.73 (-0.58%)
QQQ   222.70 (-0.84%)
AAPL   318.31 (-0.29%)
FB   217.95 (-0.82%)
MSFT   165.04 (-1.01%)
GOOGL   1,466.17 (-1.25%)
NVDA   250.48 (-0.94%)
BABA   213.75 (-2.46%)
MU   57.76 (-2.43%)
GE   11.71 (-0.51%)
AMD   50.35 (-2.63%)
T   38.50 (-0.34%)
ACB   1.99 (-3.86%)
F   9.00 (-1.53%)
BAC   33.54 (-1.70%)
GILD   63.15 (-1.24%)
Log in

NASDAQ:VRAY - Viewray Stock Price, Forecast & News

$3.17
+0.04 (+1.28 %)
(As of 01/24/2020 04:00 PM ET)
Add
Compare
Today's Range
$3.11
Now: $3.17▼
$3.31
50-Day Range
$2.70
MA: $3.92▼
$4.60
52-Week Range
$2.12
Now: $3.17▼
$9.76
Volume2.84 million shs
Average Volume3.82 million shs
Market Capitalization$315.13 million
P/E RatioN/A
Dividend YieldN/A
Beta1.17
ViewRay, Inc designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company's software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered. Read More…

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:VRAY
Previous Symbol
CUSIPN/A
CIK1597313
Webhttp://www.viewray.com/
Phone440-703-3210

Debt

Debt-to-Equity Ratio0.62
Current Ratio3.70
Quick Ratio2.58

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$80.96 million
Price / Sales3.89
Cash FlowN/A
Price / Cash FlowN/A
Book Value$1.75 per share
Price / Book1.81

Profitability

EPS (Most Recent Fiscal Year)($0.98)
Net Income$-76,400,000.00
Net Margins-110.61%
Return on Equity-75.41%
Return on Assets-37.32%

Miscellaneous

EmployeesN/A
Outstanding Shares99,410,000
Market Cap$315.13 million
Next Earnings Date3/12/2020 (Estimated)
OptionableOptionable

Receive VRAY News and Ratings via Email

Sign-up to receive the latest news and ratings for VRAY and its competitors with MarketBeat's FREE daily newsletter.

NASDAQ:VRAY Rates by TradingView

Viewray (NASDAQ:VRAY) Frequently Asked Questions

What is Viewray's stock symbol?

Viewray trades on the NASDAQ under the ticker symbol "VRAY."

How were Viewray's earnings last quarter?

Viewray Inc (NASDAQ:VRAY) posted its earnings results on Tuesday, November, 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.06. The business had revenue of $20.90 million for the quarter, compared to analyst estimates of $20.66 million. Viewray had a negative net margin of 110.61% and a negative return on equity of 75.41%. The company's revenue for the quarter was up 18.1% on a year-over-year basis. During the same period in the prior year, the company posted ($0.39) EPS. View Viewray's Earnings History.

When is Viewray's next earnings date?

Viewray is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for Viewray.

What guidance has Viewray issued on next quarter's earnings?

Viewray updated its fourth quarter 2019 Pre-Market earnings guidance on Monday, January, 13th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $17-17 million, compared to the consensus revenue estimate of $18.27 million.

What price target have analysts set for VRAY?

9 brokerages have issued 1-year price targets for Viewray's stock. Their forecasts range from $5.00 to $9.00. On average, they anticipate Viewray's stock price to reach $6.44 in the next year. This suggests a possible upside of 103.3% from the stock's current price. View Analyst Price Targets for Viewray.

What is the consensus analysts' recommendation for Viewray?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Viewray in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Viewray.

What are Wall Street analysts saying about Viewray stock?

Here are some recent quotes from research analysts about Viewray stock:
  • 1. According to Zacks Investment Research, "ViewRay Inc. is a medical device company. The company develops advanced radiation therapy technology for the treatment of cancer. MRIdian system provides continuous soft-tissue imaging during treatment. ViewRay Inc. is headquartered in Oakwood Village, Ohio. " (11/16/2019)
  • 2. Northland Securities analysts commented, "We remain confident in our analysis of the clinical benefits of MRgRT, and this study is another data point towards long-term validation." (8/19/2019)
  • 3. Cantor Fitzgerald analysts commented, ": We reiterate our Overweight rating and $13 PT on VRAY. 1Q revenue of $20.3MM (-23%) was essentially in line with FactSet consensus of $20.4MM. We think the order beat is a better measure of the momentum of the business. VRAY received orders for seven MRIdians, two more than we were expecting for the second straight quarter. We think the order momentum is a direct result of the strategy that the new management team has implemented since taking over in July 2018. The finishing touches of management’s strategy are still coming together, but we think VRAY is positioned to capitalize on what we expect to be meaningful shift to adaptive therapy and MR linacs." (5/2/2019)

Has Viewray been receiving favorable news coverage?

Press coverage about VRAY stock has trended somewhat positive on Friday, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Viewray earned a news sentiment score of 1.3 on InfoTrie's scale. They also gave media stories about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the next few days. View News Stories for Viewray.

Who are some of Viewray's key competitors?

What other stocks do shareholders of Viewray own?

When did Viewray IPO?

(VRAY) raised $52 million in an initial public offering (IPO) on the week of April 6th 2015. The company issued 4,000,000 shares at $12.00-$14.00 per share. Cowen and Company and Stifel acted as the underwriters for the IPO and BTIG and Brean Capital were co-managers.

Who are Viewray's major shareholders?

Viewray's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Rhenman & Partners Asset Management AB (0.75%), Pennsylvania Trust Co (0.13%), Alpine Global Management LLC (0.08%) and Falcon Point Capital LLC (0.06%). Company insiders that own Viewray stock include Fmr Llc, International Ltd Fosun, James F Dempsey, Orbimed Advisors Llc, Scott William Drake and Shahriar Matin. View Institutional Ownership Trends for Viewray.

Which institutional investors are buying Viewray stock?

VRAY stock was purchased by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, Alpine Global Management LLC, Falcon Point Capital LLC and Pennsylvania Trust Co. Company insiders that have bought Viewray stock in the last two years include International Ltd Fosun, Scott William Drake and Shahriar Matin. View Insider Buying and Selling for Viewray.

How do I buy shares of Viewray?

Shares of VRAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Viewray's stock price today?

One share of VRAY stock can currently be purchased for approximately $3.17.

How big of a company is Viewray?

Viewray has a market capitalization of $315.13 million and generates $80.96 million in revenue each year. The company earns $-76,400,000.00 in net income (profit) each year or ($0.98) on an earnings per share basis. View Additional Information About Viewray.

What is Viewray's official website?

The official website for Viewray is http://www.viewray.com/.

How can I contact Viewray?

Viewray's mailing address is 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH, 44146. The company can be reached via phone at 440-703-3210 or via email at [email protected]


MarketBeat Community Rating for Viewray (NASDAQ VRAY)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  252 (Vote Outperform)
Underperform Votes:  190 (Vote Underperform)
Total Votes:  442
MarketBeat's community ratings are surveys of what our community members think about Viewray and other stocks. Vote "Outperform" if you believe VRAY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VRAY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/24/2020 by MarketBeat.com Staff

Featured Article: Percentage Decliners
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel